Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka Pharmaceutical
Biotech
Otsuka pays Ionis $65M for European rights to rare disease drug
Otsuka is paying $65M upfront for European licensing rights to Ionis' donidalorsen, a treatment being developed for hereditary angioedema.
Gabrielle Masson
Dec 19, 2023 10:18am
Otsuka eye disease strategy takes Shape with $1.5B biobucks deal
Sep 8, 2023 8:45am
Otsuka takes on new Mindset for $59M, delving into psychedelics
Sep 1, 2023 10:55am
UK's Astex adds onto Merck cancer collab for $35M upfront
Aug 8, 2023 4:00am
Former BMS R&D chief Vessey jumping to Flagship—Chutes & Ladders
Jul 14, 2023 9:30am
Akebia is taking the fight to the FDA months after rejection
Nov 4, 2022 12:02pm